← Back to Search

Kinase Inhibitor

Treatment (pemigatinib) for Mantle Cell Lymphoma

Phase 2

Waitlist Available

Led By Narendranath Epperla, MD, MS

Research Sponsored by Narendranath Epperla

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 years

Awards & highlights

Study Summary

This trial is testing a drug called pemigatinib to see how well it works in treating patients with mantle cell lymphoma (MCL) or marginal zone lymphoma (MZL) that has

Who is the study for?

This trial is for patients with specific types of lymphoma—Mantle Cell Lymphoma (MCL) or Marginal Zone Lymphoma (MZL)—that have either returned after treatment or haven't responded to previous treatments. Detailed eligibility criteria are not provided.Check my eligibility

What is being tested?

The trial is testing the effectiveness of pemigatinib, a drug that may inhibit cancer cell growth by blocking certain enzymes. It includes collecting biospecimens, bone marrow aspirations and biopsies, as well as CT and PET scans to monitor progress.See study design

What are the potential side effects?

Specific side effects for pemigatinib are not listed here, but such drugs can commonly cause fatigue, nausea, diarrhea, liver issues, and changes in blood counts which could lead to increased infection risk.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Overall response rate (ORR)

Secondary outcome measures

Complete response (CR) rate

Duration of response (DOR)

Incidence of adverse events (AEs)

+2 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (pemigatinib)Experimental Treatment6 Interventions

Patients receive pemigatinib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also under CT and PET or PET/CT and blood sample collection at screening and on study. Patients may also undergo bone marrow aspirate and biopsy during screening and on study.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Bone Marrow Aspiration

2011

Completed Phase 2

~1740

Bone Marrow Biopsy

2021

Completed Phase 2

~10

Biospecimen Collection

2004

Completed Phase 2

~1730

Pemigatinib

2022

Completed Phase 2

~220

Positron Emission Tomography

2008

Completed Phase 2

~2240

Computed Tomography

2017

Completed Phase 2

~2720

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Narendranath EpperlaLead Sponsor

1 Previous Clinical Trials

Narendranath Epperla, MD, MSPrincipal InvestigatorOhio State University Comprehensive Cancer Center

1 Previous Clinical Trials

20 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available vacancies for patient participation in this clinical trial?

"As per the details available on clinicaltrials.gov, patient enrollment for this investigation is currently closed. Initially published on April 30th, 2024, with the most recent revision dated March 7th, 2024. While recruitment for this specific study is paused now, it's worth noting that there are approximately 2590 other ongoing clinical trials actively seeking participants."

Answered by AI

What is the level of safety associated with pemigatinib therapy in individuals?

"Based on our evaluation at Power, the safety rating for Treatment (pemigatinib) is 2. This assessment stems from it being a Phase 2 trial where some safety data exists; however, there is no evidence yet regarding efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Pemigatinib for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma or Marginal Zone Lymphoma

Narendranath Epperla 2024. "Pemigatinib for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma or Marginal Zone Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06300528.

All > Marginal Zone Lymphoma > Mantle Cell Lymphoma